Safety, Tolerability and Pharmacokinetic Study of Biota-CS-8958
NCT00311714 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40
Last updated 2018-05-30
Summary
This study will look at the safety, tolerability and what the body does to CS-8958 given to 40 healthy volunteers 18-55 years old. CS-8958 is a dry-powder investigational drug that is breathed into the lungs through an inhaler device. The researchers will collect information about any problems that volunteers have while taking the drug and about changes in blood pressure and how the heart is working. Volunteers will have breathing tests, physical examinations, and blood samples collected for laboratory tests. The researchers will also look at how much of the medication travels throughout the body versus how much stays only in the lungs. Doses of the medication will be tested at one level and then at higher and higher levels after a safety committee reviews the safety and tolerability information on volunteers prior to the next higher dose being given. Each volunteer will participate for up to 6 weeks from initial screening to the follow up visit and spend 7 days in the clinic.
Conditions
Interventions
- DRUG
-
CS-8958 formulated as dry powder
- OTHER
-
Placebo
Sponsors & Collaborators
-
National Institute of Allergy and Infectious Diseases (NIAID)
collaborator NIH -
Biota Scientific Management Pty Ltd
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2007-04-30
- Completion
- 2007-12-31
Countries
- United Kingdom
Study Locations
More Related Trials
-
Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok
NCT00539981 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine (LAIV) in Adults Aged 18-59 Years Post-Vaccination
NCT07133802 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
BPL-1357 Against H1N1 Influenza Virus Challenge
NCT07215858 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults
NCT04956575 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.
NCT06178991 ·Status: COMPLETED ·Phase: PHASE3
-
Single Dose Escalating Study of DAS181 in Adults
NCT00527865 ·Status: COMPLETED ·Phase: PHASE1
-
Post-marketing Study of Lyophilized Nasal Spray Live Attenuated Influenza Vaccine
NCT06280144 ·Status: RECRUITING ·Phase: PHASE4
-
Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults
NCT00125944 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy Adults
NCT01995695 ·Status: COMPLETED ·Phase: PHASE1
-
Safety Study of Live Attenuated Influenza Vaccine, CodaVax, Delivered Via Intranasal Spray
NCT04146623 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Safety of H1N1 Monovalent Vaccine (MEDI3414) in Healthy Adults
NCT00945893 ·Status: COMPLETED ·Phase: PHASE4
-
Studying Cell Immune Responses to a Live Flu Vaccine in Healthy Adults
NCT01730144 ·Status: COMPLETED
-
Influenza Antiviral DAS-181-F04 in Healthy Adults
NCT01651494 ·Status: COMPLETED ·Phase: PHASE1
-
Bifidobacterium Lactis HN019 Supplementation for Prevention of Influenza Infection in Healthy Adults
NCT01258842 ·Status: UNKNOWN ·Phase: PHASE3
-
Intramuscular CodaVax-H1N1 in Healthy Adults
NCT05223179 ·Status: COMPLETED ·Phase: PHASE1
-
Immunogenicity, Safety and Tolerability of CSL Limited Inactivated Influenza Vaccine in Adults
NCT00333398 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older
NCT01949090 ·Status: COMPLETED ·Phase: PHASE2
-
Immunogenicity and Safety Study of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults
NCT00989287 ·Status: COMPLETED ·Phase: PHASE3
-
A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine in Healthy Adults
NCT05397119 ·Status: COMPLETED ·Phase: PHASE1
-
A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old
NCT05375838 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Adults Aged >= 18 and <= 64, Plus Revaccination
NCT00889889 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of the Safety and Efficacy of a Monoclonal Antibody to Treat Influenza
NCT03903718 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older
NCT07121192 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Safety, Reactogenicity, and Immunogenicity of Inactivated Influenza A/H7/N7 Vaccine in Healthy Adults
NCT00546585 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Prospective Study to Evaluate the Safety of a New Monovalent Intranasal Influenza Vaccine
NCT00873912 ·Status: COMPLETED ·Phase: PHASE4